Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Lazari Capital Management Inc.

Lazari Capital Management Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 68.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,463 shares of the biopharmaceutical company's stock after selling 7,665 shares during the quarter. Lazari Capital Management Inc.'s holdings in Gilead Sciences were worth $320,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. State Street Corp raised its position in shares of Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. FMR LLC raised its position in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC grew its stake in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after buying an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Gilead Sciences by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock worth $650,009,000 after buying an additional 224,960 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Bank of America restated a "buy" rating and set a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an "outperform" rating and a $105.00 target price on the stock. Finally, Morgan Stanley raised Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.39.

Insider Activity

In related news, insider Merdad Parsey sold 164,211 shares of the firm's stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 in the last ninety days. Company insiders own 0.29% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $1.61 during trading on Thursday, reaching $98.04. 4,517,842 shares of the company's stock traded hands, compared to its average volume of 6,905,398. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $122.18 billion, a PE ratio of 1,089.33, a P/E/G ratio of 1.37 and a beta of 0.18. The company has a 50-day simple moving average of $92.86 and a 200-day simple moving average of $86.41.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same period last year, the firm earned $2.29 EPS. The company's quarterly revenue was up 7.0% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.